i-Base home
Search Menu
  • Home
  • HTB
  • 2018
  • February
  • 09

HTB

9 February 2018

Contents

Editorial

  • 09 February 2018: vol 19 no 3

Antiretrovirals

  • Bictegravir approved in the US in new integrase-inhibitor based FDC (Biktarvy)
  • US approve a lower-dose efavirenz (400 mg) based generic FDC (Simfi Lo)
  • ViiV announces phase 3 study switching to dolutegravir/3TC dual therapy from TAF-containing ART
  • US darunavir label updated: drug interactions and pregnancy

Treatment access

  • 75% of WHO essential medicines could be cheaper: UK and South Africa both overpay
  • London clinic to prescribe generic PrEP privately at £55 for 30 tablets

Pregnancy

  • New HIV pregnancy study uses latest ART: IMPAACT 2010 study (VESTED) includes dolutegravir and tenofovir alafenamide (TAF)
  • Association between timing of maternal ART and risk of infants born small for gestational age in Dutch ATHENA cohort

Guidelines

  • BHIVA standards of HIV care (2018): online for comment
  • UK HIV pregnancy guidelines (2018): online for comment

On the web

  • HIV conversations in the UK
  • Women in Science: IAS feature
  • Yale CRIT conference: blogs on the threats from changes to drug regulation in the US and Europe

PDFs

  • 09 February 2018: vol 19 no 3
  • HTB RSS

Early access

  • Promising data for multipurpose technologies to prevent HIV and pregnancy 24 February 2021
  • Community murals in Soweto on dolutegravir-based ART: an i-Base collaboration 22 February 2021
  • Timothy Ray Brown: a virtual memorial 21 February 2021
  • Main COVID-19 variants and their likely impacts on vaccines 16 February 2021
  • All early access reports

Current issues

  • February 2021
  • January 2021
  • December 2020
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook